Health Condition 1: C229- Malignant neoplasm of liver, not specified as primary or secondary
Conditions
Interventions
Intervention1: Terlipressin Drug Group: Intravenous Terlipressin 1 mg infusion by 50 ml syringe over 2 hours every 6 hours for 48 hours starting after induction of anaesthesia.
Control Intervention1:
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed with liver tumors Expected resection of at least three liver segments OR posterior sectionectomy Age above 18 years ASA class I-III.
Exclusion criteria
Exclusion criteria: Preoperative severe renal failure (estimated glomerular filtration rate Severe liver dysfunction (Child-Turcotte-Pugh grade C). Uncontrolled hypertensive (Blood Pressure >180/90) patients on treatment. Recent myocardial infarction (within 6 month), severe valvular heart disease. Any history of intracranial bleeding. Preoperative hyponatremia. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Acute Kidney Injury after liver resection as per KDIGO classificationTimepoint: Within 72 hours after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence of post-hepatectomy liver failure (PHLF) at day 5 of surgery, 2. length of stay in ICU (number of days), 3. length of stay in hospital (number of days), 4. Postoperative complications as per Clavein Dindo Class 5. 30 daysâ?? mortality 6. Incidence and details of any adverse event Timepoint: Upto 30 days after surgery | — |
Countries
India
Contacts
Public ContactDR SOHAN LAL SOLANKI
Tata Memorial Hospital Mumbai
Outcome results
None listed